Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Joshua Thurman to Humans

This is a "connection" page, showing publications Joshua Thurman has written about Humans.

 
Connection Strength
 
 
 
1.010
 
  1. Petr V, Thurman JM. The role of complement in kidney disease. Nat Rev Nephrol. 2023 12; 19(12):771-787.
    View in: PubMed
    Score: 0.024
  2. Harrison RA, Harris CL, Thurman JM. The complement alternative pathway in health and disease-activation or amplification? Immunol Rev. 2023 01; 313(1):6-14.
    View in: PubMed
    Score: 0.023
  3. Thurman JM, Harrison RA. The susceptibility of the kidney to alternative pathway activation-A hypothesis. Immunol Rev. 2023 01; 313(1):327-338.
    View in: PubMed
    Score: 0.023
  4. Thurman JM, Fremeaux-Bacchi V. Alternative pathway diagnostics. Immunol Rev. 2023 01; 313(1):225-238.
    View in: PubMed
    Score: 0.023
  5. Stenson EK, Kendrick J, Dixon B, Thurman JM. The complement system in pediatric acute kidney injury. Pediatr Nephrol. 2023 05; 38(5):1411-1425.
    View in: PubMed
    Score: 0.023
  6. Campbell RE, Thurman JM. The Immune System and Idiopathic Nephrotic Syndrome. Clin J Am Soc Nephrol. 2022 12; 17(12):1823-1834.
    View in: PubMed
    Score: 0.023
  7. Renner B, Laskowski J, Poppelaars F, Ferreira VP, Blaine J, Antonioli AH, Hannan JP, Kovacs JM, van Kooten C, You Z, Pickering MC, Holers VM, Thurman JM. Factor H related proteins modulate complement activation on kidney cells. Kidney Int. 2022 12; 102(6):1331-1344.
    View in: PubMed
    Score: 0.023
  8. Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, Ronco P, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2022 04; 79(4):570-581.
    View in: PubMed
    Score: 0.021
  9. Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S, Panzer SE, Zhong W, Cravedi P, Cantarelli C, Kulik L, You Z, Satchell S, Rovin B, Liu F, Kalled SL, Holers VM, Jalal D, Thurman JM. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Renal Physiol. 2021 10 01; 321(4):F505-F516.
    View in: PubMed
    Score: 0.021
  10. Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol. 2022 03; 37(3):521-535.
    View in: PubMed
    Score: 0.021
  11. Jalal D, Sanford B, Renner B, Ten Eyck P, Laskowski J, Cooper J, Sun M, Zakharia Y, Spitz D, Dokun A, Attanasio M, Jones K, Thurman JM. Detection of pro angiogenic and inflammatory biomarkers in patients with CKD. Sci Rep. 2021 04 22; 11(1):8786.
    View in: PubMed
    Score: 0.021
  12. Thurman JM. Rhabdomyolysis and complement-once again, epithelial cells take center stage. Kidney Int. 2021 03; 99(3):537-539.
    View in: PubMed
    Score: 0.020
  13. Thurman JM. BLISS in the Treatment of Lupus Nephritis. Clin J Am Soc Nephrol. 2021 06; 16(6):969-971.
    View in: PubMed
    Score: 0.020
  14. Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol. 2020 12; 128:175-187.
    View in: PubMed
    Score: 0.020
  15. Laskowski J, Renner B, Pickering MC, Serkova NJ, Smith-Jones PM, Clambey ET, Nemenoff RA, Thurman JM. Complement factor H-deficient mice develop spontaneous hepatic tumors. J Clin Invest. 2020 08 03; 130(8):4039-4054.
    View in: PubMed
    Score: 0.020
  16. Thurman JM. Complement and the Kidney: An Overview. Adv Chronic Kidney Dis. 2020 03; 27(2):86-94.
    View in: PubMed
    Score: 0.019
  17. Stites E, Renner B, Laskowski J, Le Quintrec M, You Z, Freed B, Cooper J, Jalal D, Thurman JM. Complement fragments are biomarkers of antibody-mediated endothelial injury. Mol Immunol. 2020 02; 118:142-152.
    View in: PubMed
    Score: 0.019
  18. Grafals M, Thurman JM. The Role of Complement in Organ Transplantation. Front Immunol. 2019; 10:2380.
    View in: PubMed
    Score: 0.019
  19. Laskowski J, Philbrook HT, Parikh CR, Thurman JM. Urine complement activation fragments are increased in patients with kidney injury after cardiac surgery. Am J Physiol Renal Physiol. 2019 09 01; 317(3):F650-F657.
    View in: PubMed
    Score: 0.018
  20. Thurman JM, Panzer SE, Le Quintrec M. The role of complement in antibody mediated transplant rejection. Mol Immunol. 2019 08; 112:240-246.
    View in: PubMed
    Score: 0.018
  21. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019; 10:672.
    View in: PubMed
    Score: 0.018
  22. Thurman J, Gueler F. Recent advances in renal imaging. F1000Res. 2018; 7.
    View in: PubMed
    Score: 0.018
  23. Thurman JM. Complement Biomarkers of Hemolytic Uremic Syndrome-If Not One Thing, Maybe Another. Mayo Clin Proc. 2018 10; 93(10):1337-1339.
    View in: PubMed
    Score: 0.017
  24. Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM. Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2018 07 13; 7(14).
    View in: PubMed
    Score: 0.017
  25. Tomlinson S, Thurman JM. Tissue-targeted complement therapeutics. Mol Immunol. 2018 10; 102:120-128.
    View in: PubMed
    Score: 0.017
  26. Thurman JM. A Patient with Hemolytic Uremic Syndrome and Kidney Failure. Clin J Am Soc Nephrol. 2018 06 07; 13(6):933-936.
    View in: PubMed
    Score: 0.017
  27. Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017 11; 69(11):2102-2113.
    View in: PubMed
    Score: 0.016
  28. Thurman JM, Laskowski J. Complement factor H-related proteins in IgA nephropathy-sometimes a gentle nudge does the trick. Kidney Int. 2017 10; 92(4):790-793.
    View in: PubMed
    Score: 0.016
  29. Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. 2017 Jan 01; 32(suppl_1):i57-i64.
    View in: PubMed
    Score: 0.015
  30. Thurman JM, Nester CM. All Things Complement. Clin J Am Soc Nephrol. 2016 10 07; 11(10):1856-1866.
    View in: PubMed
    Score: 0.015
  31. Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016 10; 90(4):746-52.
    View in: PubMed
    Score: 0.015
  32. Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
    View in: PubMed
    Score: 0.015
  33. Stites E, Le Quintrec M, Thurman JM. The Complement System and Antibody-Mediated Transplant Rejection. J Immunol. 2015 Dec 15; 195(12):5525-31.
    View in: PubMed
    Score: 0.014
  34. Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H. Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One. 2015; 10(9):e0136558.
    View in: PubMed
    Score: 0.014
  35. Thurman JM. Getting over our Immune-Complex - C5a receptor blockade is the answer. Cell Mol Immunol. 2017 03; 14(3):319-320.
    View in: PubMed
    Score: 0.014
  36. Thurman JM. Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2015 Jan; 65(1):156-68.
    View in: PubMed
    Score: 0.013
  37. Thurman JM. New anti-complement drugs: not so far away. Blood. 2014 Mar 27; 123(13):1975-6.
    View in: PubMed
    Score: 0.013
  38. McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol. 2013 Nov; 33(6):543-56.
    View in: PubMed
    Score: 0.012
  39. Thurman JM, Serkova NJ. Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging. Adv Chronic Kidney Dis. 2013 Nov; 20(6):488-99.
    View in: PubMed
    Score: 0.012
  40. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013 May; 123(5):2218-30.
    View in: PubMed
    Score: 0.012
  41. Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanovic D, Holers VM, Thurman JM. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol. 2013 Feb; 24(3):393-406.
    View in: PubMed
    Score: 0.012
  42. Thurman JM, Rohrer B. Noninvasive detection of complement activation through radiologic imaging. Adv Exp Med Biol. 2013; 735:271-82.
    View in: PubMed
    Score: 0.012
  43. Sargsyan SA, Thurman JM. Molecular imaging of autoimmune diseases and inflammation. Mol Imaging. 2012 Jun; 11(3):251-64.
    View in: PubMed
    Score: 0.011
  44. Thurman JM, Renner B. Dynamic control of the complement system by modulated expression of regulatory proteins. Lab Invest. 2011 Jan; 91(1):4-11.
    View in: PubMed
    Score: 0.010
  45. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010 Dec; 56(6):1168-74.
    View in: PubMed
    Score: 0.010
  46. Thurman JM, Renner B, Kunchithapautham K, Holers VM, Rohrer B. Aseptic injury to epithelial cells alters cell surface complement regulation in a tissue specific fashion. Adv Exp Med Biol. 2010; 664:151-8.
    View in: PubMed
    Score: 0.009
  47. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009 Dec; 4(12):1920-4.
    View in: PubMed
    Score: 0.009
  48. Thurman JM, Renner B, Kunchithapautham K, Ferreira VP, Pangburn MK, Ablonczy Z, Tomlinson S, Holers VM, Rohrer B. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem. 2009 Jun 19; 284(25):16939-16947.
    View in: PubMed
    Score: 0.009
  49. Thurman JM, Parikh CR. Peeking into the black box: new biomarkers for acute kidney injury. Kidney Int. 2008 Feb; 73(4):379-81.
    View in: PubMed
    Score: 0.008
  50. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol. 2007 Apr; 123(1):7-13.
    View in: PubMed
    Score: 0.008
  51. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006 Feb 01; 176(3):1305-10.
    View in: PubMed
    Score: 0.007
  52. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006 Feb; 116(2):357-68.
    View in: PubMed
    Score: 0.007
  53. Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int. 2005 Feb; 67(2):524-30.
    View in: PubMed
    Score: 0.007
  54. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005 Jan; 42(1):87-97.
    View in: PubMed
    Score: 0.007
  55. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol. 2004 Jun; 41(2-3):147-52.
    View in: PubMed
    Score: 0.006
  56. Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
    View in: PubMed
    Score: 0.006
  57. Yandamuri SS, Filipek B, Obaid AH, Lele N, Thurman JM, Makhani N, Nowak RJ, Guo Y, Lucchinetti CF, Flanagan EP, Longbrake EE, O'Connor KC. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight. 2023 06 08; 8(11).
    View in: PubMed
    Score: 0.006
  58. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med. 2003 May; 114(7):588-98.
    View in: PubMed
    Score: 0.006
  59. Kulik L, Renner B, Laskowski J, Thurman JM, Michael Holers V. Highly pathogenic natural monoclonal antibody B4-IgM recognizes a post-translational modification comprised of acetylated N-terminal methionine followed by aspartic or glutamic acid. Mol Immunol. 2023 05; 157:112-128.
    View in: PubMed
    Score: 0.006
  60. Stenson EK, Edelstein CL, You Z, Miyazaki-Anzai S, Thurman JM, Dixon BP, Zappitelli M, Goldstein SL, Akcan Arikan A, Kendrick J. Urine Complement Factor Ba Is Associated with AKI in Critically Ill Children. Kidney360. 2023 03 01; 4(3):326-332.
    View in: PubMed
    Score: 0.006
  61. Franzin R, Stasi A, Sallustio F, Bruno S, Merlotti G, Quaglia M, Grandaliano G, Pontrelli P, Thurman JM, Camussi G, Stallone G, Cantaluppi V, Gesualdo L, Castellano G. Extracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells. Am J Transplant. 2022 09; 22(9):2139-2157.
    View in: PubMed
    Score: 0.006
  62. Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol. 2022; 13:869725.
    View in: PubMed
    Score: 0.006
  63. Schriek P, Ching AC, Moily NS, Moffat J, Beattie L, Steiner TM, Hosking LM, Thurman JM, Holers VM, Ishido S, Lahoud MH, Caminschi I, Heath WR, Mintern JD, Villadangos JA. Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science. 2022 02 11; 375(6581):eabf7470.
    View in: PubMed
    Score: 0.005
  64. Peterson JN, Boackle SA, Taitano SH, Sang A, Lang J, Kelly M, Rahkola JT, Miranda AM, Sheridan RM, Thurman JM, Rao VK, Torres RM, Pelanda R. Elevated Detection of Dual Antibody B Cells Identifies Lupus Patients With B Cell-Reactive VH4-34 Autoantibodies. Front Immunol. 2022; 13:795209.
    View in: PubMed
    Score: 0.005
  65. Stenson EK, You Z, Reeder R, Norris J, Scott HF, Dixon BP, Thurman JM, Frazer-Abel A, Mourani P, Kendrick J. Complement Activation Fragments Are Increased in Critically Ill Pediatric Patients with Severe AKI. Kidney360. 2021 12 30; 2(12):1884-1891.
    View in: PubMed
    Score: 0.005
  66. Fogueri U, Charkoftaki G, Roda G, Tuey S, Ibrahim M, Persaud I, Wempe MF, Brown JM, Thurman JM, Anchordoquy TJ, Joy MS. An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. Drug Deliv Transl Res. 2022 06; 12(6):1445-1454.
    View in: PubMed
    Score: 0.005
  67. Tuey SM, Atilano-Roque A, Charkoftaki G, Thurman JM, Nolin TD, Joy MS. Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia. Xenobiotica. 2021 Jun; 51(6):657-667.
    View in: PubMed
    Score: 0.005
  68. Angeletti A, Cantarelli C, Petrosyan A, Andrighetto S, Budge K, D'Agati VD, Hartzell S, Malvi D, Donadei C, Thurman JM, Gale?ic-Ljubanovic D, He JC, Xiao W, Campbell KN, Wong J, Fischman C, Manrique J, Zaza G, Fiaccadori E, La Manna G, Fribourg M, Leventhal J, Da Sacco S, Perin L, Heeger PS, Cravedi P. Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis. J Exp Med. 2020 09 07; 217(9).
    View in: PubMed
    Score: 0.005
  69. Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Front Immunol. 2020; 11:1460.
    View in: PubMed
    Score: 0.005
  70. Frid MG, McKeon BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorhe P, Leopold JA, Wang RS, Holers VM, Stenmark KR. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 01 15; 201(2):224-239.
    View in: PubMed
    Score: 0.005
  71. Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147.
    View in: PubMed
    Score: 0.005
  72. Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018 07 01; 315(1):L1-L10.
    View in: PubMed
    Score: 0.004
  73. Antonioli AH, White J, Crawford F, Renner B, Marchbank KJ, Hannan JP, Thurman JM, Marrack P, Holers VM. Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol. 2018 01 01; 200(1):316-326.
    View in: PubMed
    Score: 0.004
  74. Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA. Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res. 2018 01 01; 78(1):143-156.
    View in: PubMed
    Score: 0.004
  75. Kataria A, Levine D, Wertenteil S, Vento S, Xue J, Rajendiran K, Kannan K, Thurman JM, Morrison D, Brody R, Urbina E, Attina T, Trasande L, Trachtman H. Exposure to bisphenols and phthalates and association with oxidant stress, insulin resistance, and endothelial dysfunction in children. Pediatr Res. 2017 Jun; 81(6):857-864.
    View in: PubMed
    Score: 0.004
  76. Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. PLoS One. 2016; 11(11):e0166200.
    View in: PubMed
    Score: 0.004
  77. Klepacki J, Klawitter J, Klawitter J, Karimpour-Fard A, Thurman J, Ingle G, Patel D, Christians U. Amino acids in a targeted versus a non-targeted metabolomics LC-MS/MS assay. Are the results consistent? Clin Biochem. 2016 Sep; 49(13-14):955-61.
    View in: PubMed
    Score: 0.004
  78. Li D, Zou L, Feng Y, Xu G, Gong Y, Zhao G, Ouyang W, Thurman JM, Chao W. Complement Factor B Production in Renal Tubular Cells and Its Role in Sodium Transporter Expression During Polymicrobial Sepsis. Crit Care Med. 2016 May; 44(5):e289-99.
    View in: PubMed
    Score: 0.004
  79. Blatt AZ, Saggu G, Kulkarni KV, Cortes C, Thurman JM, Ricklin D, Lambris JD, Valenzuela JG, Ferreira VP. Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. J Immunol. 2016 06 01; 196(11):4671-4680.
    View in: PubMed
    Score: 0.004
  80. Klepacki J, Klawitter J, Klawitter J, Thurman JM, Christians U. A high-performance liquid chromatography-tandem mass spectrometry-based targeted metabolomics kidney dysfunction marker panel in human urine. Clin Chim Acta. 2015 Jun 15; 446:43-53.
    View in: PubMed
    Score: 0.003
  81. Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther. 2015 Jun; 23(6):1066-1076.
    View in: PubMed
    Score: 0.003
  82. Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol. 2014 Aug; 25(8):1786-98.
    View in: PubMed
    Score: 0.003
  83. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fr?meaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodr?guez de C?rdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int. 2013 Dec; 84(6):1079-89.
    View in: PubMed
    Score: 0.003
  84. Zou L, Feng Y, Li Y, Zhang M, Chen C, Cai J, Gong Y, Wang L, Thurman JM, Wu X, Atkinson JP, Chao W. Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J Immunol. 2013 Dec 01; 191(11):5625-35.
    View in: PubMed
    Score: 0.003
  85. Berman N, Lectura M, Thurman J, Reinecke J, Raff AC, Melamed ML, Reinecke J, Quan Z, Evans T, Meyer TW, Hostetter TH. A zebrafish model for uremic toxicity: role of the complement pathway. Blood Purif. 2013; 35(4):265-269.
    View in: PubMed
    Score: 0.003
  86. Bohra R, Klepacki J, Klawitter J, Klawitter J, Thurman JM, Christians U. Proteomics and metabolomics in renal transplantation-quo vadis? Transpl Int. 2013 Mar; 26(3):225-41.
    View in: PubMed
    Score: 0.003
  87. Kunchithapautham K, Bandyopadhyay M, Dahrouj M, Thurman JM, Rohrer B. Sublytic membrane-attack-complex activation and VEGF secretion in retinal pigment epithelial cells. Adv Exp Med Biol. 2012; 723:23-30.
    View in: PubMed
    Score: 0.003
  88. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH. Identification of a central role for complement in osteoarthritis. Nat Med. 2011 Nov 06; 17(12):1674-9.
    View in: PubMed
    Score: 0.003
  89. Kenyon KD, Cole C, Crawford F, Kappler JW, Thurman JM, Bratton DL, Boackle SA, Henson PM. IgG autoantibodies against deposited C3 inhibit macrophage-mediated apoptotic cell engulfment in systemic autoimmunity. J Immunol. 2011 Sep 01; 187(5):2101-11.
    View in: PubMed
    Score: 0.003
  90. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM, Tomlinson S, Holers VM. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
    View in: PubMed
    Score: 0.002
  91. Moyer AL, Ramadan RT, Thurman J, Burroughs A, Callegan MC. Bacillus cereus induces permeability of an in vitro blood-retina barrier. Infect Immun. 2008 Apr; 76(4):1358-67.
    View in: PubMed
    Score: 0.002
  92. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de C?rdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, W?rzner R, Zipfel PF. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007 Sep; 18(9):2447-56.
    View in: PubMed
    Score: 0.002
  93. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006 Sep 04; 203(9):2165-75.
    View in: PubMed
    Score: 0.002
  94. J?rgensen TN, Thurman J, Izui S, Falta MT, Metzger TE, Flannery SA, Kappler J, Marrack P, Kotzin BL. Genetic susceptibility to polyI:C-induced IFNalpha/beta-dependent accelerated disease in lupus-prone mice. Genes Immun. 2006 Oct; 7(7):555-67.
    View in: PubMed
    Score: 0.002
  95. Jacobson KC, Thurman J, Schmidt CM, Rickel E, Oliviera de Ferreira J, Ferreira-da-Cruz MF, Daniel-Ribeiro CT, Howard RF. A study of antibody and T cell recognition of rhoptry-associated protein-1 (RAP-1) and RAP-2 recombinant proteins and peptides of Plasmodium falciparum in migrants and residents of the state of Rondonia, Brazil. Am J Trop Med Hyg. 1998 Aug; 59(2):208-16.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)